EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Development and Application of a Rep ‐Targeted SYBR Green I qPCR Assay for Porcine Circovirus 4: Etiological Investigation in China (2022–2025) and Molecular Evolutionary Analysis

Yi Lu, Yanhong Chen, Tong Xu, Yang Zeng, Ling Dong, Zhijing Mei, Xuexiang Yu, Suphot Wattanaphansak, Wentao Li, Qigai He

Transboundary and Emerging Diseases · 2026-01 · 2026 (1)

DOI: 10.1155/tbed/4853360 ↗
AbstractBibliografische Angaben

Abstract

Porcine circovirus (PCV) type 4 (PCV4) is an emerging Circovirus whose epidemiological and evolutionary dynamics remain incompletely characterized. We developed a replication‐associated protein ( Rep )‐targeted SYBR Green I real‐time quantitative PCR assay that showed analytical specificity against tested common porcine pathogens and an estimated 95% limit of detection of 8.22 copies/µL. Among the 1920 diagnostic samples collected from 29 Chinese provinces between 2022 and 2025, 96 tested positive for PCV4 (5.00%; 95% confidence interval [CI]: 4.11%–6.07%). The highest observed positivity was in sows, although rates did not differ significantly among production stages. The capsid ( Cap ) gene‐based phylogenetic analysis indicated that most analyzed sequences belonged to PCV4a. Exploratory Bayesian analyses estimated a global time to the most recent common ancestor around 1996.6 and an evolutionary rate of 4.76 × 10 −4 substitutions/site/year. Discrete phylogeographic reconstruction identified model‐inferred migration links rather than verified transmission routes. Three candidate positively selected sites (Ser27, Ser53, and Val98) overlapped predicted structural or epitope‐associated regions. Overall, the assay provides a practical molecular tool for PCV4 surveillance, and the epidemiological and evolutionary findings generate hypotheses for future systematic sampling, recombination‐aware genomic analysis, and investigation of possible vertical transmission.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →